Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details)

v3.21.1
SEGMENT INFORMATION (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
segment
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Segment Reporting Information [Line Items]      
Number of operating segments | segment 2    
Product sales, net $ 4,844 $ 8,270  
Gross profit 2,358 4,008  
Research and development 186 1,509  
Selling, general and administrative 5,285 7,819  
Operating Loss (3,113) (5,320)  
Goodwill 2,788   $ 2,788
Consumer Products Segment      
Segment Reporting Information [Line Items]      
Product sales, net 4,844 8,270  
Gross profit 2,358 4,008  
Research and development 128 305  
Selling, general and administrative 5,270 7,810  
Operating Loss (3,040) (4,107)  
Specialty Pharmaceutical Segment      
Segment Reporting Information [Line Items]      
Product sales, net 0 0  
Gross profit 0 0  
Research and development 58 1,204  
Selling, general and administrative 15 9  
Operating Loss (73) $ (1,213)  
Goodwill 2,800   2,800
Intangible assets $ 3,700   $ 3,700